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Background: Antipsychotic medications, particularly second-generation antipsychotics, are increasingly being used
to alleviate the symptoms of schizophrenia and other severe mental disorders in the pediatric population. While
evidence-based approaches examining efficacy and safety outcomes have been reported, no review has evaluated
prolactin-based adverse events for antipsychotic treatments in schizophrenia and schizophrenia spectrum disorders.
Methods/design: Searches involving MEDLINE, EMBASE, CENTRAL, PsycINFO, and clinical trial registries
(ClinicalTrials.gov, Drug Industry Document Archive [DIDA], International Clinical Trials Registry Platform [ICTRP]) will
be used to identify relevant studies. Two reviewers will independently screen abstracts and relevant full-text articles
of the papers identified by the initial search according to the prospectively defined eligibility criteria. Data extraction
will be conducted in duplicate independently. Pairwise random effects meta-analyses and network meta-analyses
will be conducted on individual drug and class effects where appropriate.
Discussion: This systematic review will evaluate prolactin-based adverse events of first- and second-generation
antipsychotics in the pediatric population with schizophrenia and schizophrenia spectrum disorders. It will also
seek to strengthen the evidence base of the safety of antipsychotics by incorporating both randomized controlled
trials and observational studies.
Systematic review registration: PROSPERO CRD42014009506
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Antipsychotics are a cornerstone in the treatment of patients
with severe mental disorders, including schizophrenia
and other schizophrenia spectrum disorders. The pediatric
use of antipsychotics has substantially increased since
the introduction of second-generation antipsychotics
(SGAs) (also known as ‘atypical’ antipsychotics), despite
limited evidence supporting their efficacy and safety in* Correspondence: edruyts@uottawa.ca
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unless otherwise stated.this population [1,2]. In Canada, the prevalence of
antipsychotic use in those aged 18 years or younger
increased from 1.9 per 1,000 in 1999 to 7.4 per 1,000
in 2008, with more than 70% of these prescriptions
being written by general practitioners [3], despite the
lack of approval for pediatric use by Health Canada. As
such, there is a need for post-marketing surveillance
activities of antipsychotic use in children [4].
Children may be more susceptible to antipsychotic
adverse effects than adults largely due to developmental
physiological changes that occur in childhood. However,
few studies have systematically monitored the safety ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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been considered a safer alternative to first-generation anti-
psychotics (FGAs) (also known as ‘typical’ antipsychotics)
due to their lower tendency to induce neurological effects.
However, other equally problematic adverse effects
have been associated with SGAs, leading experts to have
concerns about the proper utilization of these agents,
especially in pediatric patients [6,7].
SGAs elevate serum prolactin via dopamine antagonism
[8-10]. Studies have shown that risperidone, for example,
may elevate prolactin to a greater extent and more fre-
quently than other SGAs in pediatric and adult populations
[11-14]. Prolonged and substantial elevation of prolactin is
associated with a number of adverse effects. Direct effects of
elevated prolactin on breast tissue may lead to galactorrhea
in women and gynecomastia in men [15]. Other
effects include amenorrhea, sexual dysfunction, and
osteoporosis in women and erectile dysfunction and
impaired spermatogenesis in men [16]. Interaction of
antipsychotic drugs with dopamine receptors is thought to
be important for their mechanisms of action, leading
to both therapeutic and adverse effects [17-19]. Good
evidence supports the existence of both metabolic
and neurological adverse effects in children treated with
these medications [20].
In 2011, a group known as the Canadian Alliance
for Monitoring Effectiveness and Safety of Antipsychotics in
Children (CAMESA) published management recommenda-
tions for metabolic complications associated with SGA use
in pediatric patients [21]. They discussed that elevated
levels of prolactin may be associated with adverse
events such as gynecomastia, galactorrhea, infertility,
menstrual irregularities, oligomenorrhea, amenorrhea,
sexual dysfunction, decreased libido, acne, and hirsutism
in females [21]. However, hyperprolactinemia may be
asymptomatic, particularly in a pre-pubescent population.
The authors acknowledge that the evidence base of
clinical consequences of elevated prolactin levels is sparse,
and therefore, their recommendations on how to manage
patients with hyperprolactinemia are based on expert
consensus opinion [21].
Although risperidone is approved for use in pediatric
patients in the United States, it is not approved for use in
this population in Canada. Despite this, there is considerable
off-label use of risperidone in Canadian pediatric patients
[22]. To date, no systematic reviews have comparatively
examined the prolactin-related adverse event profiles
of both the FGAs and SGAs in schizophrenia and
schizophrenia spectrum disorder pediatric patients. The
hypothesis of a correlation between the dopamine receptor
affinity of these agents and an increase in the risk of
prolactin-related adverse events has also not been tested.
With the increased off-label use of these medications, it is
important that we further examine whether one or moreof these drugs may produce unreasonable risks to pediatric
patients. The information generated by the proposed
systematic review can help to determine the necessary
follow-up steps to minimize risks associated with the
elevated prolactin levels linked to certain antipsychotics.Methods/design
Objective
The objective of the proposed project is to examine the
risk of prolactin-related adverse events associated with
the use of antipsychotic medications for the treatment of
schizophrenia and schizophrenia spectrum disorders in
pediatric patients. We propose the use of meta-analytic
techniques to compare the frequencies of prolactin-related
adverse events associated with each of the antipsychotics.
We will conduct our analyses using two approaches: (1)
considering each drug independently and (2) considering
all drugs within a given dopamine receptor affinity class as
exhibiting comparable treatment effects.Eligibility criteria
Eligibility criteria for study selection are described accord-
ing to the population-intervention-comparators-outcomes-
study design (PICOS) structure. Specifically, published
studies comparing relevant interventions in human subjects
will be eligible if the following criteria are met:Population
Pediatric patients (children and adolescents aged 5–18
years) diagnosed with schizophrenia and schizophrenia
spectrum disorders will be considered.
Note that antipsychotic monotherapy is acknowledged
as the treatment of choice for patients with schizophrenia
[23]. Given the propensity for polypharmacy in other
conditions, such as bipolar disorder, schizophrenia is
the key focus in an attempt to ensure the true effect
of antipsychotics on prolactin-related adverse events
is examined.Interventions/comparisons
Commonly used FGAs and SGAs will be considered
(see Table 1). Placebo and no treatment will be considered
to be relevant comparator treatments, where applicable.Outcomes
Outcomes will include prolactin-related adverse events:
gynecomastia, galactorrhea, sexual dysfunction (impotence/
decreased libido), menstrual irregularities (amenorrhea/
dysmenorrhea), change in prolactin levels, and any other
prolactin-related adverse event reported in the included
studies.





Chlorpromazine (Thorazine) Aripiprazole (Abilify)
Fluphenazine (Prolixin) Asenapine (Saphris)
Haloperidol (Haldol) Clozapine (Clozaril)
Loxapine (Loxitane) Iloperidone (Fanapt)
Molindone (Moban) Olanzapine (Zyprexa)
Perphenazine (Trilafon) Paliperidone (Invega, Invega Sustenna)
Thioridazine (Mellaril) Risperidone (Risperdal)
Thiothixene (Navane) Quetiapine (Seroquel)
Trifluoperazine (Stelazine) Ziprasidone (Geodon)
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Both clinical trials and prospective observational studies
will be included as data may be limited if we were to
restrict to one study design. Data from both designs
may be meta-analyzed together if they report common
information; however, based on preliminary scoping and
readings, we anticipate conducting a variety of analyses.
The study lengths of follow-up and reporting times of
outcomes will inform the choice of time duration upon
which analyses will be based. Multiple time points are
feasible, and it is expected that some studies will have
limited follow-up.
Literature search and study selection
We have developed electronic search strategies with
the assistance of a medical librarian at the University of
Ottawa for the following databases: MEDLINE, EMBASE,
CENTRAL, and PsycINFO. Our search strategies consist of
terms related to the specific interventions of interest and a
pediatric patient population (see the Appendix for the
MEDLINE/EMBASE search strategy). No schizophrenia
terms are used in the search strategy in order to be inclusive
of all schizophrenia and schizophrenia spectrum disorders.
With changes of the Diagnostic and Statistical Manual of
Mental Disorders (DSM) over time, the definitions and
diagnostic criteria of schizophrenia and schizophrenia
spectrum disorders have evolved [24]. The bibliographies
of all identified relevant studies will be used to perform a
recursive search of the literature.
We will also conduct a comprehensive gray litera-
ture search. This will include clinical trial registries
(ClinicalTrials.gov and International Clinical Trials
Registry Platform [ICTRP]), drug industry documentation
(Drug Industry Document Archive [DIDA]), and publically
available clinical study reports (CSRs).
Articles will be assessed according to the prospectively
defined eligibility criteria by two independent reviewers
using pre-designed eligibility forms. Abstracts of papers
identified by the initial search will be evaluated by thelead reviewer for appropriateness to the study question,
and all potentially relevant papers will be obtained and
evaluated in detail.
Data extraction
After relevant studies have been identified, we will meet
as a group to ensure eligibility. Data extraction will be
conducted in duplicate independently. Among included
studies, we will extract data on the study design and
inclusion criteria, intervention dosage, pill count, control
(if appropriate), features of patient status (e.g., age,
gender, race, co-morbidities, functional status indicators,
recovery rates), duration of follow-up, co-interventions,
and outcomes of interest. The outcomes of interest (e.g.,
gynecomastia, galactorrhea, sexual dysfunction, menstrual
irregularities, and change in prolactin levels) will be
extracted individually rather than as a composite of
prolactin-related adverse events. We are aware that some
outcomes may be rarely reported. The non-reporting of a
particular outcome will not constitute the reporting of a
zero count. Trials that do not report a particular outcome
will not be included in the subsequent analyses.
Assessment of risk of bias
We will assess the validity of included trials using the
Cochrane risk of bias instrument. This instrument
evaluates six key domains: sequence generation; allocation
concealment; blinding of participants, personnel, and
outcome assessors; incomplete outcome data; selective
outcome reporting; and other sources of bias [25].
We will modify response options for assessment of
blinding by substituting ‘probably yes’ and ‘probably no’
for ‘unclear,’ as we have recently demonstrated that this
approach can enhance the assessment of blinding in
randomized trials [26].
We will employ the Grading of Recommendations
Assessment, Development and Evaluation (GRADE)
system for rating the overall quality of evidence [27]. For
each outcome, randomized trials begin as high-quality
evidence but may be rated down by one or more of five
categories of limitations: (1) risk of bias, (2) consistency,
(3) directness, (4) imprecision, and (5) reporting bias.
The quality of evidence for each main outcome can be
determined after considering each of these elements and
can be categorized as either high (we are very confident
that the true effect lies close to that of the estimate of
the effect), moderate (we are moderately confident in the
effect estimate: the true effect is likely to be close to the
estimate of the effect, but there is a possibility that it is
substantially different), low (our confidence in the effect
estimate is limited: the true effect may be substantially
different from the estimate of the effect), or very low
(we have very little confidence in the effect estimate:
the true effect is likely to be substantially different
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use of the recent paper by Salanti et al. to determine the
quality of evidence from a network meta-analysis [28]. We
will include (1) the key role of indirect comparisons,
(2) the contributions of each piece of direct evidence to
the network meta-analysis estimates of effect size, (3)
the importance of the transitivity assumption to the
validity of network meta-analysis, and (4) the possibility
of disagreement between direct evidence and indirect
evidence [28].
For included observational studies, we will assess the val-
idity of the individual studies using the Newcastle-Ottawa
Scale (NOS) [29]. This instrument is used to assess
selection of patients, comparability of cohorts (or cases
and controls), and adequacy of outcomes/exposures [29].
Evidence synthesis
We will conduct our analyses using two different
approaches: (1) considering each drug as independent and
(2) considering all drugs within a given dopamine receptor
affinity class as exhibiting comparable treatment effects.
The first approach will allow us to examine if specific
drugs exhibit a certain effect over others. Although this is
a naïve approach that will ignore the fact that drugs
of a similar classification are likely to exhibit similar
magnitudes of treatment effect, there is evidence that
certain antipsychotic drugs of the same class have differing
adverse event profiles. The second approach will allow us
to examine a critical pharmacokinetic property, dopamine
receptor affinity, which is highly linked to the regulation
of prolactin release.
Statistical model for clinical trial data
Pairwise meta-analysis and, where appropriate, network
meta-analysis will be conducted for each prolactin-
related adverse event outcome. Network meta-analyses
gain their strength from utilizing evidence from all available
randomized control trials (RCTs) that have compared any
treatment of interest to a control intervention (e.g., placebo)
or head-to-head with another treatment of interest [30,31].
Network meta-analyses thus allow for strong inferences
about comparative effectiveness between all interventions,
even when interventions have never or rarely been
compared head-to-head [31].
Placebo/no therapy will be used as the reference therapy.
Posterior densities for unknown parameters will be esti-
mated using Markov chain Monte Carlo (MCMC) methods.
Non-informative or vague prior distributions will be used
throughout, allowing the data to drive the final inferences.
Addressing heterogeneity
Primary analyses will be unadjusted analyses, and then
additional analyses to assess heterogeneity will be pursued
[32]. A feasibility assessment of the distribution of studyand patient characteristics that may affect treatment ef-
fects across direct comparisons of the evidence networks
will be conducted [33]. We will first create a list of
potential treatment effect modifiers for the interventions of
interest based on prior knowledge or subgroup results of
individual studies before comparing results between studies.
Next, the distribution of study and patient characteristics
that are determined to be likely effect modifiers will
be compared across studies to identify any potential
imbalances between different types of direct comparisons.
Where possible, sensitivity analyses will be undertaken if
there are important variations in the definitions of the
outcomes across studies. Furthermore, where feasible,
meta-regression will be incorporated into the models to
test and (potentially) control for effect modification.
Secondary analysis using observational data
To incorporate observational data, a two-stage approach
will be applied. First, all comparisons informed by
observational data will be meta-analyzed using pairwise
random effects meta-analysis. From each of these pairwise
meta-analyses, an approximate normal distribution of the
mean log odds ratio will be generated with some mean
and variance estimates. Second, the generated approximate
distribution will be used as a prior distribution for
the particular comparison (i.e., log odds ratio) in the
Bayesian network meta-analysis model described above.
As sensitivity analyses, less information versions using the
same means but twice and four times the estimated
variances (i.e., half and a quarter of the precision) will
also be carried out.
Reporting of findings
Full graphical and numeric presentations of findings
along with a layperson’s summary will be provided to
convey the results of our work. This will include the
following: network diagrams showing the availability
of evidence for all possible treatment comparisons;
summary odds ratios and 95% credible intervals for
all pairwise comparisons, both in tabular form and in
forest plots; and estimates of probabilities that each
therapy is deemed ‘best’ for each outcome along with
associated average rankings of efficacy and safety; these
will be described using approaches recommended by
Salanti et al. [34].
Discussion
This proposed review will add to the literature in several
ways. Many existing reviews of pediatric populations focus
solely on the efficacy and tolerability outcomes [35,36]. To
our knowledge, prolactin-related adverse events have only
briefly been assessed in prior meta-analyses of antipsychotic
drugs. Seida et al. completed a comparative effectiveness
review on antipsychotic use in a combined pediatric
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outcomes, prolactin-related and sexual side effects (amen-
orrhea, oligomenorrhea, erectile dysfunction, decreased
libido, hirsutism, breast symptoms, galactorrhea, prolactin
levels) were combined and analyzed together [37].
Furthermore, only efficacy outcomes were stratified by
indication; safety outcomes were analyzed by drug
class for all indications. Other studies report changes in
prolactin levels but not specifically in schizophrenia or
schizophrenia spectrum disorders [20,38,39]. Therefore,
this proposed review allows us to (1) inform treatment
guidelines for pediatric schizophrenia and schizophrenia
spectrum disorder and (2) provide evidence for specific
prolactin-related adverse events.
Furthermore, the comparative risks between newer
and older antipsychotics have not been well defined
as of yet. A systematic approach to quantifying the
risks for both groups will provide the safety perspective
required for clinicians to make evidence-based treatment
decisions.
There are a few potential limitations of this planned
review. Clinical expertise and preliminary review of
some of the relevant studies for this research shows that
in many cases, while patients are randomized to one
active antipsychotic medication to address the study’s
research question, additional concomitant medications
for the treatment of their disorder may be prescribed to
patients at physicians’ discretion. While these additional
treatments may have implications for additional effects
seen, outcome data for those remaining strictly on the
prescribed treatments may not be available. This will be
a limiting factor of the purity of some of the included trial
data. We will address this issue by exploring the associated
frequencies and reasons for changes.
The largest studies available will likely be retrospective
observational studies and, as such, may be prone to various
degrees of residual confounding due to the lack of complete
information (e.g., severity of patients’ condition, timing of
drug use, co-morbidities). While it will be feasible to
capture and comment on the extent of information
collected and adjusted for, the impact of any missing
information will not be evaluable.
As the majority of existing evidence on antipsychotic
medications is from adult populations, the results of
this systematic review and meta-analyses will be of interest
to key stakeholders, policy makers, researchers, and
clinicians working in pediatric mental health care.
With the growing need for age-specific research in
schizophrenia and schizophrenia spectrum disorders,
this review seeks to highlight prolactin-related adverse
event profiles in the pediatric population and to strengthen
the evidence base of the safety of antipsychotics by




2. (Infant* or infancy or Newborn* or Baby* or Babies
or Neonat* or Preterm*).mp.
3. exp Child/
4. (Child* or Schoolchild* or School age* or
Preschool* or Kid or kids or Toddler*).mp.
5. exp Adolescent/
6. Adoles*.ti,ab.




11. (Pubert* or Pubescen* or Prepubescen*).mp.
12. exp Pediatrics/
13. (Pediatric* or Paediatric* or Peadiatric*).mp.
14. exp Schools/
15. (Nursery school* or Kindergar* or Primary school*
or Secondary school* or Elementary school* or
High school* or Highschool*).mp.
16. or/1-15
17. exp Adolescent/ and exp Adult/
18. or/1-4,6-15
19. 17 not 18
20. 16 not 19
21. chlorpromazine/
22. (chlorpromazine or Thorazine or Largactil or
Megaphen).ti,ab,kw.
23. fluphenazine/
24. (fluphenazine or Prolixin).ti,ab,kw.
25. haloperidol/
26. (haloperidol or Haldol or Sernace or Haldol*).ti,ab,
kw.
27. loxapine/
28. (loxapine or loxitine or Loxapac or Loxitane or
Adasuve).ti,ab,kw.
29. molindone/
30. (molindone or Moban or Moban*).ti,ab,kw.
31. perphenazine/
32. (perphenazine or Trilafon or Trilafon*).ti,ab,kw.
33. thioridazine/
34. (thioridazine or Mellaril or Melleril or Sonapax or
Thioril).ti,ab,kw.
35. thiothixene/
36. (thiothixene or tiotixene or Navane).ti,ab,kw.
37. trifluoperazine/
38. (trifluoperazine or Eskazinyl or Eskazine or
Jatroneural or Modalina or Stelazine or Terfluzine
or Trifluoperaz or Triftazin).ti,ab,kw.
39. aripiprazole/
40. (aripiprazole or Abilify or Aripiprex).ti,ab,kw.
41. asenapine/
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43. clozapine/
44. (clozapine or Clozaril or Clozaril*).ti,ab,kw.
45. iloperidone/
46. (iloperidone or Fanapt or Fanapta or Zomaril or
Fanapt*).ti,ab,kw.
47. olanzapine/
48. (olanzapine or Lanzek or Zypadhera or Oleanz or
Zyprexa).ti,ab,kw.
49. paliperidone/
50. (paliperidone or Invega or Invega*).ti,ab,kw.
51. risperidone/
52. (risperidone or Risperdal or Risperdal Consta or
Risperdal M-Tab or Risperdal Quicklets or Risper-
dal*).ti,ab,kw.
53. quetiapine/
54. (quetiapine or Seroquel or Seroquel*).ti,ab,kw.
55. ziprasidone/
56. (ziprasidone or Geodon or Zeldox or Zipwell or
Geodon*).ti,ab,kw.
57. or/21-56
58. 20 and 57
59. limit 58 to human [Limit not valid in CCTR;
records were retained]
60. limit 59 to english language
61. remove duplicates from 60
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